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012.08.0Abstract Background and aim: The plasma concentrations of N-terminal pro-brain natriuretic
peptide (NT-proBNP) can reﬂect the cardiac functions in patients with cardiac diseases. Our aim
is to assess the value of NT-proBNP in the diagnosis of heart failure and evaluation of cardiac func-
tions in pediatric patients with ventricular septal defect (VSD).
Patients and method: The study comprised 40 children with VSD (mean age 12 ± 5 months) and 20
healthy children as a control group. Detailed echocardiographic examination was performed and
the level of NT-proBNP level was measured.
Results: The plasma level of NT-proBNP was signiﬁcantly higher in patients with VSD than in
control subjects (P< 0.05). Also, it was signiﬁcantly increased in VSD patients with congestive
heart failure (CHF) than those without heart failure (P< 0.05). Moreover, NT-proBNP level
increased with increasing severity of clinical symptoms. There were positive correlations between
NT-proBNP level and left ventricular end diastolic diameter, left ventricular end systolic diameter,
estimated systolic pulmonary artery pressure and VSD size and negative correlations with ejection
fraction (EF) and fractional shortening (FS) in VSD patients with or without heart failure. The
plasma levels of NT-proBNP with cutoff value of 101 fmol/ml (854 pg/ml), predicted CHF with
a sensitivity of 90.0%, speciﬁcity of 80%, and area under ROC curve was 0.980.
Conclusion: NT-proBNP level is a good marker of disease severity and correlates with echocardio-
graphic measurements and clinical symptoms in pediatric patients with VSD.
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031. Introduction
Congenital heart diseases contribute signiﬁcantly to the dis-
ease-related morbidity and mortality in children especially in
the ﬁrst year of life.1 Ventricular septal defect (VSD) is the
most common congential heart disease (CHD) and the most
common cause of congestive heart failure (CHF) in children,
especially in infants.2g by Elsevier B.V. All rights reserved.
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results in an excessive volume load, and subsequent dilation of
the left ventricle that induces left ventricular overload. In-
creased cardiac volume and afterload are thought to be the
main pathophysiological mechanisms leading to CHF.3 Con-
gestive heart failure is a common clinical syndrome, but clini-
cal symptoms lack speciﬁcity, which is particularly true in
infants. Clinical scores are used to increase the accuracy in
the diagnosis of the disease.4
Brain natriuretic peptide (BNP) is a cardiac hormone se-
creted from the left ventricular myocardium in response to
ventricular volume expansion and pressure overload.5 It is syn-
thesized as a preprohormone, consisting of 108 amino acids;
processing releases the biologically active 32-amino acid pep-
tide and an N-terminal pro-brain natriuretic peptide.6 The
plasma concentrations of BNP and NT-proBNP can reﬂect
the cardiac function.2 NT-proBNP is a more stable structure
compared with BNP in whole blood for more than 24 h and
is not signiﬁcantly inﬂuenced by exercise and position. These
factors confer its potential as an additional tool in the assess-
ment of ventricular systolic dysfunction.7–9
Many publications described BNP as an excellent marker of
left ventricular function and a simple and effective tool to detect
heart failure (HF) or left ventricular dysfunction. Therefore, the
aim of the present study was to determine the concentrations of
NT-proBNP in pediatric patients with VSD presenting with
or without HF and to correlate the level of NT-proBNP with
their clinical and echocardiography data, aiming to assess the
diagnostic value of the new marker in these patients.
2. Methods
2.1. Study design
This case-control study was conducted during the period from
June 2010 to February 2011. It included forty patients with
VSD, selected randomly from the pediatric cardiology outpa-
tient clinic and inpatient ward of Zagazig University Hospitals.
Any child with isolated signiﬁcant VSD, with or without CHF,
was included. Exclusion criteria were: VSD with other cardiac
anomalies, chest infections, or other diseases affecting ventric-
ular function like hypertension and abnormal renal function.
Twenty healthy children without any abnormal echocardio-
graphic ﬁndings were taken as a control group. Parents gave
an informed consent before starting the study.
2.2. Clinical assessment
All children were subjected to full history taking and thorough
clinical examination which included complete cardiac exami-
nation. The severity of HF was assessed according to Modiﬁed
Ross’s Clinical score for diagnosis of HF. This score classiﬁed
patients into: No CHF= 0–2 points, Ross A (mild
CHF) = 3–6 points, Ross B (moderate CHF) = 7–9 points,
and Ross C (severe CHF) = 10–12 points.10
2.3. Echocardiographic examination
All patients underwent echocardiographic examination using
GE Vivid-7 multipurpose system with different probe sizes.
Each patient was examined according to the recommendationsof the American Society of Echocardiography.11 Echocardio-
graphic examination included M-mode, 2D, and Doppler
echocardiography. The left atrial diameter (LAD) was esti-
mated from the parasternal long axis view. The left ventricular
end systolic diameter (LVESD), left ventricular end diastolic
diameter (LVEDD),ejection fraction (EF) and fractional
shortening (FS) were measured using M-mode echocardiogra-
phy in the left parasternal view. Estimated systolic pulmonary
artery pressure (ESPAP) was calculated through Doppler trac-
ing of the peak velocity of the tricuspid regurgitation jet by
using the Bernoulli equation.12
ESPAS ¼ 4ðVÞ2 þ RAP
V= Peak velocity of the tricuspid regurgitation jet.
An arbitrary 10 mmHg is added to the gradient as the RAP.
According to relation between VSD size and Aortic annu-
lus, VSD was classiﬁed into:-
(I) Small: VSD size is usually 61/4 the size of the Aortic
Valve annulus.
(II) Moderate: VSD size is usually 1/3–2/3 the size of the
Aortic Valve annulus.
(III) Large: The VSD size is >2/3 the size of the Aortic Valve
annulus.13
2.4. Measurement of plasma level of NT-proBNP
This was done using radioimmunoassay (Roche, diagnostic
system). The blood samples were collected in chilled ethylene
diamine tetra acetic acid, placed immediately on ice, and cen-
trifuged for 20 min. The plasma was stored at 80 C before
being assayed.
2.5. Statistical analysis
Data were analyzed using Statistical Package for Social Sci-
ences (SPSS) 10.0. The quantitative data showing a normal dis-
tribution are presented as mean ± standard deviation. For
comparison between two groups mean, t-test was used. For
comparison between three groups’ means, one way ANOVA
(analysis of variance) was used. Non parametric values repre-
sented as median and range and the median of two groups was
tested by Mann–Whitney-U test, also the comparison between
three groups’ median was analyzed by Kruskall–Wallis test.
Qualitative data are represented by frequency and relative per-
centage and chi-square test was used for testing association of
qualitative data. Receiver operating curve (ROC) characteris-
tic was used to determine cut off value of NT-proBNP in heart
failure development. Correlations were performed using the
Pearson bivariate correlation. P value of < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
The study included 40 patients with VSD. They classiﬁed into 2
groups regarding the presence of CHF. Group I included
twenty VSD patients without CHF (16 males and 4 females)
and their ages ranged from 2.5 to 32 months (median:
14.5 months). Group II included twenty VSD patients with
Table 1 Demographic and clinical data of studied groups.
Variables Group I (n= 20) Group II (n= 20) Control Group (n= 20) P
Age (months) median (range) 14.5 (2.5–32) 10 (5.5–15) 13 (5–20) 0.36
Sex (M:F) 16:4 8:12 10:10 0.13
VSD Type
Perimembranous 14(70.0%) 14(70.0%) NA –
Muscular 2(10.0%) 4(20.0%) NA –
Outlet 2(10.0%) 2(10.0%) NA –
Inlet 2(10.0%) 0.0 –
VSD size (mm) mean ± SD 7.81 ± 2.46 8.71 ± 2.37 NA –
Ross score
Score IA NA 8 (40.0%) NA –
Score IB NA 6 (30.0%) NA –
Score IC NA 6 (30.0%) NA –
NA, not available.
Table 2 Comparison of echocardiographic parameters among the studied groups.
Variables Group I (n= 20)
Mean ± SD
Group II (n= 20)
Mean ± SD
Control Group (n= 20)
Mean ± SD
F P1 P2 P3
LVEDD(mm) 28.7 ± 3.92 30.9 ± 2.6 22.4 ± 3.08 36.56 <0.05 <0.05 <0.05
LVESD(mm) 18.1 ± 3.4 20.2 ± 2.5 16.00 ± 2.98 9.8 <0.05 <0.05 <0.05
EF% 71.6 ± 7.27 61.5 ± 6.66 69.6 ± 4.61 14.46 <0.05 >0.05 <0.05
FS% 35.1 ± 5.7 30.3 ± 5.7 39.2 ± 8.5 8.35 <0.05 <0.05 <0.05
ESPAP(mmHg) 45.3.3 ± 13.36 53.5 ± 13.1 23.0 ± 5.80 22.10 <0.05 <0.05 <0.05
p1 = Group I vs. Group II, p2 = Group I vs. control group, p3 = Group II vs. control group.
LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; EF, ejection fraction; FS, fractional shortening;
ESPAP, estimated systolic pulmonary artery pressure.
Table 3 Comparison of NT-proBNP level among the studied groups.
Variables Group I (n= 20) Group II (n= 20) Control Group (n= 20) Kruskal–Wallis P1 P2 P3
NT-proBNP (fmol/ml)
median(range)
55 (10–120) 830 (100–950) 32.5 (10–105) 36.56 <0.05 <0.05 <0.05
p1 = Group I vs. Group II; p2 = Group I vs. control group; p3 = Group II vs. control group.
Figure 1 Comparison between NT proBNP level in VSD with
heart failure (mild, moderate, severe) and VSD without heart
failure.
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15.5 months (median: 10 months). There were 20 normal con-
trol subjects, of whom 10 (50%) were males and 10 (50%) were
females, their ages ranged from 5 to 20 months. There were no
signiﬁcant differences between the three studied groups in
respect of age and gender (P= 0.36, P= 0.13 respectively).
In all patients, the perimembranous type of VSD was the com-
monest type. Regarding the severity of HF in group II; 8 pa-
tients had score IA, 6 had score IB, and 6 had score IC (Table 1).
Table 2 compared echocardiographic parameters between
the studied groups. There were signiﬁcant differences between
all groups regarding LVEDD, LVESD and ESPAP, also there
were signiﬁcant differences between all groups regarding the
LVEF and the LVFS except that between VSD patient without
HF and control group.
The plasma levels of NT-proBNP were signiﬁcantly higher
in VSD patients with or without HF than in controls (830 vs.
32.5 fmol/ml, P< 0.05 and 55 vs. 32.5 fmol/ml, P< 0.05,
respectively). Also, it was signiﬁcantly higher in VSD patients
with HF than in those without HF (830 vs. 55 fmol/ml,
Table 5 Correlation between NT-proBNP and echocardio-
graphic data in the two patients groups.
Variables Group I Group II
R P R P
LVEDD 0.457 <0.05 0.558 <0.05
LVESD 0.538 <0.05 0.538 <0.05
EF 0.595 <0.05 -0.683 <0.05
FS 0.680 <0.05 -0.599 <0.05
ESPAP 0.567 <0.05 0.503 <0.05
VSD size 0.585 <0.05 0.450 <0.05
LVEDD, left ventricular end diastolic diameter; LVESD, left ven-
tricular end systolic diameter; EF, ejection fraction.
FS, fractional shortening; ESPAP, estimated systolic pulmonary
artery pressure.
Table 4 Relation between clinical Ross score and NT-proBNP concentration in group II.






Kruskal–Wallis P1 P2 P3
NT-proBNP (fmol/ml)
median(range)
675(100–850) 830 (240–950) 950 (230–950) 13.9 >0.05 <0.05 <0.05
p1 = Ross score A vs. Ross score B; p2 = Ross score B vs. Ross score C; p3 = Ross score A vs. Ross score C.
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proBNP levels were given in fmol/ml; in order to convert the
results of NT-proBNP from fmol/ml to pg/ml; results should
be multiplied by factor 8.457 (Fig. 1).
Moreover, the plasma level of NT-proBNP increased with
increasing severity of the clinical symptom as it was signiﬁ-
cantly higher in Ross score C than Ross score B (950 vs.
830 fmol/ml, P< 0.001) while there was an insigniﬁcant dif-Figure 2 ROC curve for NT-proBNP as a diagnostic marker of
CHF with a cut-off point at 101 fmol/ml.ference between Ross score B and Ross score A (830 vs.
675 fmol/ml, P value > 0.05) (Table 4).
In Group I and II, there were positive correlations between
NT-proBNP level and LVEDD, LVESD, ESPAP and VSD
size, and there were negative correlations between NT-proBNP
level and LVEF and LVFS (Table 5).
The plasma levels of NT-proBNP with cutoff value of
101 fmol/ml (854 pg/ml), predicted CHF with a sensitivity of
90.0%, speciﬁcity of 80%, and area under ROC curve was
0.980 (Fig. 2).
4. Discussion
Brain natriuretic peptide is a cardiac hormone secreted from
the ventricular myocardium as a response to ventricular vol-
ume expansion and pressure overload.5 BNP has a diuretic,
natriuretic and vasodilator activities.14 There is an increasing
interest in determining BNP and its N-terminal pro-peptide
levels not only in patients with CHF but also in patients with
CHD.15 Recent studies have reported the usefulness of the NT-
proBNP levels in predominantly adult patients with various
CHD.16,17 A few studies have been performed in children with
CHD.18 So, we conducted this study to assess the value of plas-
ma NT-proBNP in the diagnosis of CHF and evaluation of
cardiac function in pediatric patients with VSD.
In our study, the Plasma levels of NT-proBNP were signif-
icantly higher in patients with VSD with or without CHF than
in control. Also, the plasma level of NT-proBNP was signiﬁ-
cantly increased in VSD patients with CHF than in those with-
out CHF. Suda et al.,19 Kunii et al.,20 and koch et al.21 found
increasing NT-proBNP level with volume overload in infants
and children with left to right shunt and this result agreed with
our study.
Moreover, we detected signiﬁcant correlation between NT-
proBNP concentrations and the severity of clinical symptoms.
This ﬁnding was in agreement with that of Wu et al.2 study, in
which the concentration of plasma NT-proBNP was positively
correlated with the clinical CHF score in 51 patients with VSD
and with varying degree of CHF. This elevation of NT-proBNP
level results from a surge in NT-proBNP production in reaction
to the acute muscle dysfunction and increased wall tension.22
In our study, the plasma levels of NT-proBNP were corre-
lated with LVEDD, so it could reﬂect the degree of volume
overload. This volume overload may be one of the factors
leading to increased NT-proBNP levels. Also, the plasma lev-
els of NT-proBNP were correlated with LVESD. Ootaki
et al.23 found more increasing NT-proBNP with increasing
dimension of left ventricle during systole and diastole in chil-
dren with CHD.
Our data revealed increasing NT-proBNP concentrations
with decreasing left ventricular FS and EF in VSD patients
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study of Mir et al.24. They aimed to determine plasma levels
in healthy children and children with CHF. They included
31children with CHF caused by dilated cardiomyopathy,
hypoplastic left heart syndrome, postoperative tetralogy of
Fallot, mitral regurgitation, VSD, and ventricular atrio-
ventricular septal defects. They found a negative correlation
between NT-proBNP and left ventricular EF. Ajuluchukwu
et al.25 conducted a study to determine NT-proBNP levels in
Nigerian healthy adults and hospitalized CHF patients. Causes
of CHF were hypertensive heart disease, primary dilated car-
diomyopathy and myocardial infarction. NT-proBNP demon-
strated a signiﬁcant, negative relationship to both ejection
fraction (r= 0.49, P< 0.05); and fractional shortening
(r= 0.51; P< 0.05).
In our study, ESPAP was positively correlated with NT-
proBNP concentrations. Suda et al.19 and Toyono et al.26 re-
ported that NT-proBNP reﬂected pressure and volume loading
of the pulmonary artery and the right ventricle and suggested
that NT-proBNP determinations may help to identify children
with VSD complicated by pulmonary hypertension. Pulmon-
ary hypertension produces pressure overload to the right ven-
tricle thereby resulting in the enlargement of the right ventricle
and signiﬁcant pulmonary and tricuspid regurgitation. These
considerable pressure and volume overloads on the right ven-
tricle might lead to the elevation in NT-proBNP level.26
Also, our data revealed positive correlation between VSD
size and NT-proBNP concentrations. Cowley et al.,27 Ozhan
et al.,28 and Mainwaring et al.29 demonstrated a positive cor-
relation between NT-proBNP level and shunt severity in pa-
tients with left-to-right shunt lesions.
Finally, our results identiﬁed NT-proBNP level with a cut-
off value of 101 fmol/ml (854 pg/ml), predicted CHF with a
sensitivity of 90.0%, speciﬁcity of 80%, and area under ROC
curve was 0.980. It means that NT-proBNP is a more speciﬁc
and sensitive biomarker for identifying the CHF.
5. Conclusion
Plasma NT-proBNP is a valuable marker for the diagnosis of
heart failure and assessment of the severity of volume overload
in children with VSD. These ﬁndings open a new additional
diagnostic tool that could result in a more precise diagnosis
and management of CHF in children. Further studies that cor-
relate NT-proBNP levels with effects of different therapeutic
interventions could be of great importance.
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